AYTU - CIK 0001385818
AYTU BIOPHARMA, INC trades as AYTU. In its fiscal 2025 annual report the company posted revenue of $66.38M, up 1.8% from the prior year and net income of -$13.56M. This page tracks AYTU BIOPHARMA, INC through 893 SEC filings, with financial statements and metrics updated as new reports are filed.
Over the last 9 fiscal years AYTU BIOPHARMA, INC's revenue grew from $2.56M to $66.38M, a compound annual growth rate of 43.6%. Net profit margin expanded from -1099.7% to -20.4% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| Quarterly report | 10-Q | 2026-05-13 |
| Major company event | 8-K | 2026-05-13 |
| Major company event | 8-K | 2026-04-02 |
| SCHEDULE 13G/A | - | 2026-02-17 |
| SCHEDULE 13G/A | - | 2026-02-13 |
| Quarterly report | 10-Q | 2026-02-03 |
| Major company event | 8-K | 2026-02-03 |
| Major company event | 8-K | 2026-01-20 |
The largest companies sharing AYTU BIOPHARMA, INC's SEC industry classification (pharmaceutical preparations).
AYTU BIOPHARMA, INC reported revenue of $66.38M for fiscal year 2025, an increase of 1.8% year over year.
In its latest fiscal year AYTU BIOPHARMA, INC reported a net loss of $13.56M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.